279 related articles for article (PubMed ID: 9152597)
21. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Parente F; Sainaghi M; Sangaletti O; Imbesi V; Maconi G; Anderloni A; Bianchi Porro G
Aliment Pharmacol Ther; 2002 Mar; 16(3):553-7. PubMed ID: 11876710
[TBL] [Abstract][Full Text] [Related]
22. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
23. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
24. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
Hanauer G; Graf U; Meissner T
Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
[TBL] [Abstract][Full Text] [Related]
25. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
26. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
27. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
28. [Proton pump inhibitors: Pantoprazole].
Takeuchi K; Hase S
Nihon Rinsho; 2002 Feb; 60 Suppl 2():655-60. PubMed ID: 11979865
[No Abstract] [Full Text] [Related]
29. Pantoprazole and cyclosporine or tacrolimus.
Schwrer H; Lorf T; Ringe B; Ramadori G
Aliment Pharmacol Ther; 2001 Apr; 15(4):561-2. PubMed ID: 11284790
[No Abstract] [Full Text] [Related]
30. Lack of pantoprazole drug interactions in man: an updated review.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S31-50. PubMed ID: 8793602
[TBL] [Abstract][Full Text] [Related]
31. Lack of pantoprazole drug interactions in man: an updated review.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1996 Jun; 34(6):243-62. PubMed ID: 8793611
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Cao H; Wang MW; Sun LX; Ikejima T; Hu ZQ; Zhao WH
J Pharm Pharmacol; 2005 Jul; 57(7):923-7. PubMed ID: 15969954
[TBL] [Abstract][Full Text] [Related]
33. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 Feb; 34(2):51-5. PubMed ID: 8929746
[TBL] [Abstract][Full Text] [Related]
34. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
35. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
[TBL] [Abstract][Full Text] [Related]
36. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
37. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
38. Induction of microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450IVA1 (P-450LA omega) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator.
Wu HQ; Masset-Brown J; Tweedie DJ; Milewich L; Frenkel RA; Martin-Wixtrom C; Estabrook RW; Prough RA
Cancer Res; 1989 May; 49(9):2337-43. PubMed ID: 2523237
[TBL] [Abstract][Full Text] [Related]
39. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S58-66. PubMed ID: 8793604
[TBL] [Abstract][Full Text] [Related]
40. The proton-pump inhibitors: similarities and differences.
Horn J
Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
